Clinical Trial Update: Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation [Phase 1]

View source ↗

Summary

A Phase I ascending-dose study evaluating intravenous OPC-108459 in patients with atrial fibrillation was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Paroxysmal Atrial Fibrillation
• Persistent Atrial Fibrillation

Drugs mentioned

• OPC-108459 (OPC-108459)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Atrial Fibrillation, Paroxysmal Atrial Fibrillation | Phase 1 | Status: TERMINATED | Results posted: 2017-04-10